Press Releases
GT Biopharma Appoints Two New Independent Directors
GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550
GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT
GT Biopharma And Cytovance Biologics Announce Milestone Achievement
GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors
